Pharmafile Logo
Pharmafocus logo
Advanced Search

J&J

Showing 15 posts of 227 posts found.

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 26, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abcam, Alzheimer's, Dr Reddy's, GSK, J&J, JJ, Reckitt Benckiser, Remicade, Sanofi, influenza, opioid crisis, opioids, top ten, valproate

As we come to the end of January, it’s Friday again – time for another rundown of the top ten …

News
shutterstock_92671375

US court upholds ruling that J&J’s Remicade patent is invalid

January 24, 2018
Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …

News
jj_sign_on_wall

J&J withdraws controversial vaginal mesh from Australian market

January 23, 2018
Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, lawsuit, pharma, vaginal mesh

Johnson & Johnson has withdrawn its controversial vaginal mesh product from the Australian market after missing a deadline requiring all …

News
darzalex

NICE meets Janssen halfway over Darzalex

January 18, 2018
Medical Communications, Sales and Marketing J&J, JJ, Janssen, biotech, darzalex, drugs, pharma, pharmaceutical

NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes

The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …

News
xarelto_10_tablet1

Bayer and J&J successfully reverse $28 million Xarelto court payout

January 10, 2018
Research and Development, Sales and Marketing Bayer, J&J, JJ, Johnson & Johnson, Xarelto, pharma

Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

January 5, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten

Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …

News
4420456374_64a3d7e6aa

Pharmafile.com’s top ten stories of 2017

December 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit

After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …

News

J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows

December 13, 2017
Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma

Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …

News

J&J’s third quarter: The good and the bad

October 18, 2017
Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical

It was a mixed bag for Johnson & Johnson on its announcement of third quarter results. It could largely be …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 29, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten

It’s Friday, and it’s time for another round up of the most popular articles on pharmafile.com over the last seven …

News

J&J backs out of $1.1 billion hep C deal, wiping 22.2% from Achillion’s stock

September 12, 2017
Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, achillion, hepatitis C, pharma

Johnson & Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to …

News
virginia-7592

Has Trump’s power over pharma come to an end after Charlottesville?

August 31, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Donald Trump, J&J, JJ, Kenneth Frazier, MSD, President trump, Trump, life sciences, medicine, pharma, pharmaceuticals, president

In a shock move that was to have deeply resonant consequences, MSD Chairman and Chief Executive Officer Kenneth Frazier announced …

Feature

Johnson & Johnson face major lawsuit over vaginal mesh

July 4, 2017
Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, lawsuit, vaginal mesh

Johnson & Johnson will face a lawsuit after 700 Australian women launched a class action suit over the failures of …

News
actelion

Actelion spin-off hit by blow shortly before buyout

June 9, 2017
Medical Communications, Research and Development Actelion, Idorsia, J&J, JJ

Idorsia, the spin-off R&D company of Actelion, has been hit a blow even before it has left the ground. The …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026